Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 BCR-ABL
- Associated Disease
- chronic myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/344
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1
- Rating
- 5
- Evidence Type
- Predictive
- Disease
- Chronic Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Imatinib
- Evidence Level
- A
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 20537386
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Imatinib | Sensitivity | true |